South Korea
· Delayed Price · Currency is KRW Genome & Company Statistics
Total Valuation
Genome & Company has a market cap or net worth of KRW 107.00 billion. The enterprise value is 104.39 billion.
| Market Cap | 107.00B |
| Enterprise Value | 104.39B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genome & Company has 30.57 million shares outstanding. The number of shares has increased by 35.97% in one year.
| Shares Outstanding | 30.57M |
| Shares Change (YoY) | +35.97% |
| Shares Change (QoQ) | +1.68% |
| Owned by Insiders (%) | 21.80% |
| Owned by Institutions (%) | 0.72% |
| Float | 17.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.20 |
| PB Ratio | 0.91 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.76 |
| EV / Sales | 4.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.87 |
Financial Position
The company has a current ratio of 3.75, with a Debt / Equity ratio of 24.63.
| Current Ratio | 3.75 |
| Quick Ratio | 3.48 |
| Debt / Equity | 24.63 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.76 |
| Interest Coverage | -14.96 |
Financial Efficiency
Return on equity (ROE) is -32.39% and return on invested capital (ROIC) is -18.08%.
| Return on Equity (ROE) | -32.39% |
| Return on Assets (ROA) | -15.59% |
| Return on Capital (ROIC) | -18.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | 2.90 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.70% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -55.70% |
| 50-Day Moving Average | 4,479.00 |
| 200-Day Moving Average | 4,819.48 |
| Relative Strength Index (RSI) | 34.25 |
| Average Volume (20 Days) | 219,300 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genome & Company had revenue of KRW 23.92 billion and -37.88 billion in losses. Loss per share was -1,319.00.
| Revenue | 23.92B |
| Gross Profit | 12.20B |
| Operating Income | -41.79B |
| Pretax Income | -42.22B |
| Net Income | -37.88B |
| EBITDA | -33.81B |
| EBIT | -41.79B |
| Loss Per Share | -1,319.00 |
Balance Sheet
The company has 84.38 billion in cash and 27.71 billion in debt, giving a net cash position of 56.67 billion or 1,853.80 per share.
| Cash & Cash Equivalents | 84.38B |
| Total Debt | 27.71B |
| Net Cash | 56.67B |
| Net Cash Per Share | 1,853.80 |
| Equity (Book Value) | 112.49B |
| Book Value Per Share | 3,846.34 |
| Working Capital | 68.58B |
Cash Flow
In the last 12 months, operating cash flow was -18.91 billion and capital expenditures -17.48 billion, giving a free cash flow of -36.39 billion.
| Operating Cash Flow | -18.91B |
| Capital Expenditures | -17.48B |
| Free Cash Flow | -36.39B |
| FCF Per Share | -1,190.25 |
Margins
Gross margin is 51.00%, with operating and profit margins of -174.67% and -158.35%.
| Gross Margin | 51.00% |
| Operating Margin | -174.67% |
| Pretax Margin | -176.47% |
| Profit Margin | -158.35% |
| EBITDA Margin | -141.30% |
| EBIT Margin | -174.67% |
| FCF Margin | -152.09% |
Dividends & Yields
Genome & Company does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -35.97% |
| Shareholder Yield | -35.97% |
| Earnings Yield | -37.69% |
| FCF Yield | -34.01% |
Stock Splits
The last stock split was on August 6, 2024. It was a forward split with a ratio of 2.
| Last Split Date | Aug 6, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |